07:10:38 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-28 15-6 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-06-14 Ordinarie utdelning EMPLI 0.00 SEK
2023-06-13 Årsstämma 2023
2023-05-12 Kvartalsrapport 2023-Q1
2023-05-02 Extra Bolagsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-11-14 Extra Bolagsstämma 2022
2022-08-18 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-04-07 Ordinarie utdelning EMPLI 0.00 SEK
2022-04-06 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Emplicure utvecklar produkter baserat på kombinationen av redan godkända aktiva substanser och materialvetenskap inom biokeramer, med skräddarsydda frisättningsprofiler som specialitet. Moderbolaget fokuserar på läkemedel, initialt mot kronisk smärta och med egenskaper som motverkar att de kan missbrukas. Via dotterbolag utvecklas konsumentprodukter, med oralt nikotin som första produktlinje. Sortimenten riktar sig till läkemedels- och konsumentnischer.
2023-10-20 18:05:16

Emplicure AB (publ) ("Emplicure" or the "Company") has today received information that a number of shareholders in the Company, including board member Johan Wieslander, CEO Håkan Engqvist and the Company's co-founder Thomas Lundqvist, have decided to form a buyout consortium by transferring their shares in the Company to Goldcup 33922 AB (under change of name to Emplicure Holding AB) (the "Holding Company"), a newly formed company which today is wholly owned by TomEQT Private AB, in exchange for shares in the Holding Company.

According to information from the buyout consortium, shareholders who jointly hold more than 90 per cent of the total shares and votes in Emplicure have entered into agreements regarding the transfer of all their shares in the Company to the Holding Company. When settlement of all transactions has taken place, which according to the Holding Company is expected to occur shortly, the Holding Company intends to initiate squeeze-out proceedings in respect of the remaining shares in the Company and request that Emplicure applies for delisting of the Company's shares from Nasdaq First North Growth Market.

Upon receipt of such request from the Holding Company, the board of directors of Emplicure will administer and decide upon the request in accordance with applicable laws and rules. The board of directors will provide further information to the market when such becomes available.

For Johan Wieslander and Håkan Engqvist, board member and CEO of Emplicure, their transfer of shares in Emplicure to the Holding Company entails customary PDMR transaction reporting to the Swedish Financial Supervisory Authority, where the transferred shares will be reported at a price of SEK 0.41 per share, corresponding to the price at which the consortium members receive shares in the Holding Company.

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on 20 October 2023 at 18:05 CEST

For additional information, please contact

Gisela Sitbon
Chairman of the board of directors
Phone: +46 702 825 558
E-mail: gisela@sitbon.nu

Certified Adviser
Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

Emplicure uses patented bioceramic technology to develop innovative and effective products to help consumers and patients live better lives. Our consumer division makes tiny, long-lasting and flavorful nicotine pouches that can be an alternative to smoking. Our pharmaceutical division develops safer and tamper-resistant treatments for pain. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com